| Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease M Charlton, GT Everson, SL Flamm, P Kumar, C Landis, RS Brown Jr, ... Gastroenterology 149 (3), 649-659, 2015 | 967 | 2015 |
| Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection M Bourlière, SC Gordon, SL Flamm, CL Cooper, A Ramji, M Tong, ... New England Journal of Medicine 376 (22), 2134-2146, 2017 | 692 | 2017 |
| Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence F Poordad, ER Schiff, JM Vierling, C Landis, RJ Fontana, R Yang, ... Hepatology 63 (5), 1493-1505, 2016 | 580 | 2016 |
| The hepatic stem cell niche: identification by label‐retaining cell assay R Kuwahara, AV Kofman, CS Landis, ES Swenson, E Barendswaard, ... Hepatology 47 (6), 1994-2002, 2008 | 331 | 2008 |
| Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange CS Landis, X Li, FW Telang, JA Coderre, PL Micca, WD Rooney, ... Magnetic resonance in medicine 44 (4), 563-574, 2000 | 269 | 2000 |
| Equilibrium transcytolemmal water‐exchange kinetics in skeletal muscle in vivo CS Landis, X Li, FW Telang, PE Molina, I Palyka, G Vetek, CS Springer Jr Magnetic Resonance in Medicine: An Official Journal of the International …, 1999 | 253 | 1999 |
| The nonsteroidal farnesoid X receptor agonist cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis M Trauner, A Gulamhusein, B Hameed, S Caldwell, ML Shiffman, ... Hepatology 70 (3), 788-801, 2019 | 243 | 2019 |
| Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment F Poordad, F Felizarta, A Asatryan, MS Sulkowski, RW Reindollar, ... Hepatology 66 (2), 389-397, 2017 | 225 | 2017 |
| Patient characteristics and outcomes of 11 721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States MW Fried, JM Crawford, AR Mospan, SE Watkins, B Munoz, RC Zink, ... Clinical Infectious Diseases 72 (10), e558-e565, 2021 | 205 | 2021 |
| Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit F Su, L Yu, K Berry, IW Liou, CS Landis, SC Rayhill, JD Reyes, ... Gastroenterology 150 (2), 441-453. e6, 2016 | 197 | 2016 |
| Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial GM Hirschfield, O Chazouillères, JP Drenth, D Thorburn, SA Harrison, ... Journal of hepatology 70 (3), 483-493, 2019 | 173 | 2019 |
| Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension G Garcia-Tsao, J Bosch, Z Kayali, SA Harrison, MF Abdelmalek, E Lawitz, ... Journal of hepatology 72 (5), 885-895, 2020 | 157 | 2020 |
| Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial J Thompson, N Jones, A Al‐Khafaji, S Malik, D Reich, S Munoz, ... Liver Transplantation 24 (3), 380-393, 2018 | 149 | 2018 |
| Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study F Poordad, ER Schiff, JM Vierling, C Landis, RJ Fontana, R Yang, ... J Hepatol 62 (Suppl 2), S261, 2015 | 147 | 2015 |
| Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report AR Ende, NH Kim, MM Yeh, J Harper, CS Landis Journal of medical case reports 9, 1-4, 2015 | 139 | 2015 |
| DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort EC Verna, G Morelli, NA Terrault, AS Lok, JK Lim, AM Di Bisceglie, ... Journal of hepatology 73 (3), 540-548, 2020 | 134 | 2020 |
| Cure with interferon‐free direct‐acting antiviral is associated with increased survival in patients with hepatitis C virus‐related hepatocellular carcinoma from both east and west H Dang, YH Yeo, S Yasuda, CF Huang, E Iio, C Landis, DW Jun, ... Hepatology 71 (6), 1910-1922, 2020 | 81 | 2020 |
| Cholesterol crystals in hepatocyte lipid droplets are strongly associated with human nonalcoholic steatohepatitis GN Ioannou, CS Landis, GY Jin, WG Haigh, GC Farrell, R Kuver, SP Lee, ... Hepatology communications 3 (6), 776-791, 2019 | 79 | 2019 |
| Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change CE Kling, JD Perkins, CS Landis, AP Limaye, L Sibulesky American Journal of Transplantation 17 (11), 2863-2868, 2017 | 73 | 2017 |
| Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis C Frenette, Z Kayali, E Mena, PS Mantry, KJ Lucas, G Neff, M Rodriguez, ... Journal of hepatology 74 (2), 274-282, 2021 | 58 | 2021 |
